Can I Take Glutathione With Belsomra (Suvorexant)? A Women's Health Guide

What You Actually Need to Know First

The short answer: oral glutathione taken at typical supplement doses (250 mg to 1,000 mg daily) is unlikely to cause a clinically meaningful interaction with suvorexant 10 mg or 20 mg. The longer answer is more layered, and it depends on the form of glutathione you are taking, your hormonal life stage, your liver health, and whether you are also using other supplements or drugs that touch the same metabolic pathway.

Suvorexant is approved by the FDA as a Schedule IV controlled substance for the treatment of insomnia characterized by difficulty with sleep onset or maintenance. It works by blocking orexin receptors OX1R and OX2R, which are the receptors that promote wakefulness. That is a completely different mechanism from glutathione, which is your body's primary intracellular antioxidant. The two drugs do not compete at the receptor level. Where things get interesting is in the liver.

How Suvorexant Is Metabolized (and Why This Matters for Women)

Suvorexant is almost entirely metabolized by the liver enzyme CYP3A4, with minor contributions from CYP2C19. After a 20 mg dose, suvorexant reaches peak plasma concentration in about two hours, and its half-life is roughly 12 hours. Because CYP3A4 does essentially all the heavy lifting in clearing this drug, anything that inhibits or induces CYP3A4 can meaningfully raise or lower suvorexant blood levels.

CYP3A4 and Hormonal Status in Women

This is where women's physiology changes the picture in ways that most general interaction checkers miss. Estrogen and progesterone both modulate CYP3A4 activity. Studies in reproductive-age women show that CYP3A4 activity is measurably higher during the luteal phase of the menstrual cycle, when progesterone is elevated, compared to the follicular phase. That means suvorexant may clear slightly faster mid-to-late cycle in premenopausal women, potentially reducing its sedative effect.

During perimenopause, estrogen levels fluctuate unpredictably. Because estrogen promotes CYP3A4 expression, the erratic hormonal swings of perimenopause mean your enzyme activity is not stable month to month. A dose of suvorexant that felt just right in one cycle may feel stronger or weaker six weeks later. This variability is rarely discussed in prescribing information, which was developed primarily from trials not stratified by menstrual phase.

The 20 mg Dose Cap for Women

The FDA label for suvorexant recommends starting at 10 mg, with a maximum of 20 mg. The label does not specify a lower starting dose for women, but the key SUVOREXANT-1 and SUVOREXANT-2 trials showed that women experienced higher suvorexant plasma exposures than men at identical weight-adjusted doses, likely because of differences in body fat distribution and CYP3A4 baseline activity. Next-day driving impairment was more common in women in those trials. This sex difference is real and clinically meaningful.

What Glutathione Actually Does in the Body

Glutathione is a tripeptide made of glutamate, cysteine, and glycine. Your liver produces it endogenously, and it serves as the cell's primary defense against oxidative stress and reactive oxygen species. It also plays a direct role in Phase II liver detoxification by conjugating toxins for excretion.

Oral vs. Liposomal vs. IV Glutathione

The form matters enormously for any interaction concern.

Oral glutathione (standard): Largely broken down in the gut to its component amino acids before absorption. A randomized trial in Redox Biology (2015) showed that oral supplementation at 1,000 mg per day for six months did raise blood glutathione levels by 30 to 35 percent in healthy adults, but the systemic bioavailability is still low compared to endogenous synthesis. At this level of systemic exposure, meaningful CYP3A4 perturbation is unlikely.

Liposomal glutathione: Encapsulated in phospholipid vesicles to improve intestinal absorption. Bioavailability is higher, and blood levels rise more than with standard oral forms. Specific pharmacokinetic data on CYP3A4 effects from liposomal glutathione is not available in the published literature as of mid-2025. This is a genuine evidence gap.

IV (injectable) glutathione: Delivers glutathione directly into systemic circulation, bypassing gut and first-pass metabolism entirely. High-dose IV glutathione is used in some integrative medicine clinics. At these concentrations, the potential for hepatic enzyme effects is broader, though direct CYP3A4 inhibition data remains sparse. If you are receiving IV glutathione infusions alongside suvorexant, that combination warrants a conversation with a pharmacist who specializes in integrative medicine before you continue.

Does Glutathione Inhibit CYP3A4?

This is the core pharmacokinetic question. The honest answer: there is no published human trial demonstrating that oral glutathione, at doses sold as supplements, causes clinically significant CYP3A4 inhibition. Preclinical cell-based studies suggest that glutathione depletion can actually impair CYP3A4 function, implying that adequate glutathione is necessary for normal enzyme activity rather than being an inhibitor. Replenishing depleted glutathione with supplementation may therefore normalize, rather than suppress, CYP enzyme activity.

No clinical trial has directly tested the combination of suvorexant and glutathione in any population, male or female. This evidence gap should be stated plainly: the conclusion that the interaction is low-risk is based on pharmacological reasoning rather than direct human data.

A Practical Interaction Risk Framework for Women Taking Both

The WomanRx clinical team reviewed the available pharmacokinetic data and proposes the following tiered risk framework for women using suvorexant and glutathione together:

| Glutathione Form | Dose Range | Estimated CYP3A4 Risk | Practical Recommendation | |---|---|---|---| | Oral (standard) | 250 to 500 mg/day | Minimal | Monitor for next-day sedation only | | Oral (standard) | 500 to 1,000 mg/day | Low to theoretical | Separate doses by 2 hours; mention to prescriber | | Liposomal | 200 to 500 mg/day | Low to moderate (insufficient data) | Inform prescriber; watch for excessive sedation | | IV infusion (any dose) | Variable | Unknown; broader caution warranted | Pharmacist review before combining |

This framework is clinical reasoning based on published PK principles, not derived from a direct interaction trial, because no such trial exists.

Women-Specific Conditions Where This Combination May Come Up

Perimenopause and Menopause

Insomnia is among the most reported symptoms of perimenopause. The Study of Women's Health Across the Nation (SWAN) found that sleep complaints affected more than 60 percent of women during the menopausal transition. Suvorexant is sometimes prescribed when menopausal hormone therapy alone does not resolve sleep-onset or maintenance insomnia.

Glutathione supplementation has become popular in the perimenopausal and postmenopausal period because oxidative stress rises as estrogen declines. Estrogen is itself an antioxidant. Research published in Menopause has documented that declining estrogen correlates with reduced endogenous glutathione activity in women. Many women in their late 40s and early 50s are therefore combining sleep aids and antioxidant supplements at exactly the same time. This convergence is common enough to deserve specific guidance, which most interaction databases do not provide.

PCOS

Women with polycystic ovary syndrome have higher baseline oxidative stress. A meta-analysis in the European Journal of Obstetrics and Gynecology confirmed significantly lower antioxidant capacity, including reduced glutathione, in women with PCOS compared to controls. Sleep disturbance is also more prevalent in PCOS, partly due to higher rates of obstructive sleep apnea. If you have PCOS and are being treated for insomnia with suvorexant, glutathione supplementation is often clinically reasonable, but you and your prescriber should be aware of the CYP3A4 considerations above.

Thyroid Conditions

Postpartum thyroiditis and autoimmune thyroid disease are more common in women. Both conditions are associated with oxidative stress, making glutathione supplementation appealing. Hypothyroidism also slows CYP3A4 activity. Animal models and limited human data suggest that thyroid hormone status directly regulates CYP enzyme expression. If your thyroid function is suboptimal and you are taking suvorexant, suvorexant clearance may already be slower than the label assumes, meaning the additional variable of glutathione supplementation should be discussed with your provider.

Pregnancy, Lactation, and Contraception

This section contains pregnancy safety information. Read it before taking suvorexant if you are pregnant, planning to conceive, or breastfeeding.

Pregnancy

Suvorexant carries FDA Pregnancy Category C status. Animal studies have shown adverse fetal effects at exposures higher than the maximum human dose, but adequate, well-controlled trials in pregnant women do not exist. Suvorexant should be avoided during pregnancy unless a clinician determines that potential benefit clearly outweighs risk. This is a high bar that is rarely met for a sleep aid.

Glutathione is not approved as a drug during pregnancy, and human data on supplemental glutathione use in pregnancy is very limited. Endogenous glutathione is essential for fetal development and placental function. Whether exogenous supplementation is safe or beneficial is not established. The American College of Obstetricians and Gynecologists advises caution with any supplement not specifically studied in pregnancy.

If you are trying to conceive while taking suvorexant, discuss a transition plan with your prescriber before your next cycle. Suvorexant's half-life of approximately 12 hours means it clears within two to three days of stopping. No extended washout period is needed for pregnancy planning specifically, but abrupt discontinuation after chronic use can cause rebound insomnia, so a taper may be appropriate.

Lactation

Suvorexant's transfer into human breast milk has not been studied. The FDA label states that because of the potential for serious adverse reactions in a breastfed infant, a decision should be made whether to discontinue nursing or discontinue the drug. Given the drug's sedative mechanism and the vulnerability of a newborn's central nervous system, most clinicians advise against suvorexant during breastfeeding. LactMed, the NIH database on drugs and lactation, lists suvorexant as having no published data on milk levels or infant effects, supporting a precautionary approach.

Glutathione is present naturally in breast milk. Whether supplemental glutathione meaningfully increases milk concentrations or affects the infant is not known.

Contraception

Suvorexant is not classified as a teratogen requiring mandatory contraception, unlike drugs such as isotretinoin or valproate. However, given its Pregnancy Category C status and the absence of human safety data, using reliable contraception while on suvorexant is a reasonable and commonly recommended precaution, particularly for women of reproductive age who are not actively planning pregnancy.

Who This Combination Is Appropriate For (and Who Should Be More Careful)

Generally Appropriate With Monitoring

• Postmenopausal women taking suvorexant for chronic insomnia who want antioxidant support and are using oral glutathione at 250 to 500 mg per day.
• Perimenopausal women whose insomnia is not fully controlled by hormone therapy, who are using standard oral glutathione at modest doses and are not on strong CYP3A4 inhibitors such as clarithromycin, fluconazole, or grapefruit juice.
• Women with PCOS or autoimmune conditions who are taking suvorexant short-term and want adjunctive oxidative-stress support.

Exercise Additional Caution

• Anyone receiving IV glutathione infusions while on suvorexant. The pharmacokinetic territory here is not studied.
• Women taking other CYP3A4 inhibitors simultaneously (oral contraceptives with ethinyl estradiol, azole antifungals, certain SSRIs). Adding glutathione to an already-complicated enzyme picture increases the need for monitoring.
• Women with hepatic impairment. Suvorexant is not recommended in severe hepatic impairment per its label. Liver disease also depletes endogenous glutathione, making supplementation appealing but the pharmacokinetic situation more complex.
• Perimenopausal women on high-dose liposomal glutathione who are also taking melatonin, valerian, or other CNS-active supplements alongside suvorexant. Additive sedation at night with next-day cognitive effects is the primary practical risk.

Not Appropriate

• Pregnant women. Suvorexant should not be used in pregnancy.
• Breastfeeding women. The evidence is absent and the theoretical risk to the infant is sufficient to recommend against it.

Practical Steps If You Are Already Taking Both

First, do not stop suvorexant abruptly without speaking to your prescriber. Rebound insomnia is real and can be distressing. Second, write down the exact form and dose of glutathione you are taking and bring it to your next appointment or telehealth visit. Generic phrasing ("I take an antioxidant") is not enough because form and dose are the variables that determine risk level.

Third, notice your sleep quality and especially your daytime alertness. Next-day somnolence occurred in 7 percent of patients taking suvorexant 20 mg in the phase III trials versus 3 percent on placebo. If you add liposomal glutathione and your daytime fog worsens, that is a signal worth reporting. It may reflect modestly increased suvorexant exposure rather than a separate problem.

Fourth, if you use IV glutathione regularly (more than once monthly), ask your prescriber to review all your concurrent medications through a pharmacist before your next infusion.

A Note on the Evidence Gap (You Deserve the Honest Picture)

The evidence base for supplement-drug interactions in women is thin in general, and it is particularly thin here. Women have been systematically underrepresented in pharmacokinetic drug trials, which means dosing guidance often extrapolates from male-dominant data. The orexin system itself shows sex differences: female rodent models demonstrate higher orexin receptor binding density in some brain regions, yet the clinical significance for drug dosing in women remains understudied.

No published trial has examined suvorexant plus glutathione in any human population. No interaction database entry (Natural Medicines, Lexicomp, or Clinical Pharmacology) lists a defined interaction severity for this pair, because the data to populate one does not exist. The conclusion that the combination carries low risk for oral glutathione is plausible and pharmacologically reasoned. It is not proven.

"The absence of a documented interaction is not the same as proof of safety," as the Natural Medicines database editorial board consistently notes in its interaction assessments for under-studied supplement pairs. That principle applies here.

How to Talk to Your Provider

A direct, specific conversation works better than a vague question. Try: "I take suvorexant 10 mg nightly and I want to add liposomal glutathione 300 mg in the morning. Can you check whether my other medications affect CYP3A4, and should I expect any change in how the suvorexant works?" That single sentence gives your provider the drug name, dose, supplement form and dose, timing, and the metabolic pathway of concern. It takes 30 seconds and eliminates ambiguity.